Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Oncology
Biotech
Barinthus HPV-related cancer drug doesn't prove efficacy
Barinthus' high risk human papillomavirus-associated cervical cancer treatment is safe, but a phase 1 test failed to prove it actually works.
James Waldron
Apr 19, 2024 9:50am
Cullinan rebrands, halts lymphoma trial in autoimmune refocus
Apr 16, 2024 10:05am
Boundless boldly goes public with $100M IPO
Mar 28, 2024 7:10am
Theratechnologies sheds preclinical oncology research programs
Mar 25, 2024 5:30am
Pfizer revamps oncology R&D strategy
Feb 29, 2024 6:03pm
A new biotech blooms with $100M to take on small molecules
Feb 29, 2024 9:30am
More News
SCRI and AstraZeneca to collab on cancer clinical trials
Feb 29, 2024 7:05am
4 Big Pharmas recruit Biofourmis for cancer trials
Feb 14, 2024 3:30pm
Novartis will pay €2.7B to pick up cancer specialist MorphoSys
Feb 5, 2024 7:06pm
Takeda drops cancer candidates amid shifting treatment landscape
Feb 2, 2024 5:33am
See more stories